Gilead Sciences, Inc.
Foreign stocks · NASDAQ · Healthcare · Pharmaceuticals
Researches and makes HIV antivirals, hepatitis drugs and certain cancer drugs. Its main revenue comes from patented drugs sold to hospitals and pharmacies through large US distributors
For every 100 dollars of sales: cost of sales 21 · operating expenses 45 · other income adds 0 · tax and other items 5 · leaving 29 as net profit
Investors in Thailand can buy GILD through 10 mutual funds open to retail investors. Most of them (10 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds GILD.
| Fund | GILD weight | How it invests | 1-year return |
|---|---|---|---|
 SCBIHEALT(SSFE)SCB Healthcare Innovation | 5.08% | Via BNP Paribas Funds Health Care Innovators | +15.53% |
 DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND | 4.79% | Via Janus Henderson Horizon Biotechnology Fund | +2.88% |
 MHEALTHGMFC Health Innovation Fund | 3.81% | Via BGF World Healthscience Fund | +17.59% |
| MHEALTHRMFMFC Health Innovation Retirement Fund | 3.72% | Via BGF World Healthscience Fund | +18.34% |
 LHHEALTH-ALH HEALTH INNOVATION FUND | 3.61% | Via AB International Health Care Portfolio | +18.58% |
 TUSHEALTH-ATISCO US Healthcare Fund | 2.98% | Via XLV | +23.08% |
 ASP-IHEALTHAsset Plus Innovative Healthcare Fund | 2.84% | Via several master funds (JHHBIU2 LX, ARKG US) | +20.72% |
| TGHSTARPTISCO Global Healthcare Stars Plus Fund | 2.31% | Via several master funds (BlackRock Global Funds - World Healthscience) | +15.44% |
 BCAP-XHEALTHBCAP NEXT GEN Health Fund | 1.32% | Via several master funds | +17.62% |
 PWINPHILLIP WORLD INNOVATION FUND | 1.32% | Via several master funds | +15.27% |
Yearly average over the last 4 years · Latest annual sales 29.4B USD
For every 100 dollars of sales, about 29 dollars is left as net profit
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
Now close to its 1-year high
| Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenue | 27.3B USD | 27.3B USD | 27.1B USD | 28.8B USD | 29.4B USD |
| Gross profit | 20.7B USD | 21.6B USD | 20.6B USD | 22.5B USD | 23.2B USD |
| Operating profit | 9.9B USD | 7.3B USD | 7.6B USD | 1.7B USD | 10.0B USD |
| Net profit | 6.2B USD | 4.6B USD | 5.7B USD | 480.0M USD | 8.5B USD |
| EPS (diluted) | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| Gross margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Operating margin | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| Operating cash flow | 11.4B USD | 9.1B USD | 8.0B USD | 10.8B USD | 10.0B USD |
| Free cash flow | 10.8B USD | 8.3B USD | 7.4B USD | 10.3B USD | 9.5B USD |
| Total assets | 68.0B USD | 63.2B USD | 62.1B USD | 59.0B USD | 59.0B USD |
| Total liabilities | 46.9B USD | 42.0B USD | 39.4B USD | 39.7B USD | 36.4B USD |
| Shareholders' equity | 21.1B USD | 21.2B USD | 22.7B USD | 19.2B USD | 22.6B USD |
| Period | SMA | EMA | Price vs line |
|---|---|---|---|
| 10 days | 163.93 | 165.27 | Above |
| 20 days | 158.31 | 160.32 | Above |
| 50 days | 152.30 | 152.94 | Above |
| 100 days | 142.54 | 146.55 | Above |
| 200 days | 140.59 | 139.43 | Above |
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 73.59 | Down |
| MACD(12,26) | 5.67 | Up |
| ADX(14) | 32.13 | Neutral |
| ATR(14) % of price | 1.58 | Neutral |
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
MFC2TISCOASSET2SCBAM1DAOLINV1LHFUND1ASSETFUND1BBLAM1PAMC1| Fund | GILD weight | Master fund | 1-year return | TER |
|---|---|---|---|---|
| SCBIHEALT(SSFE) | 5.08% | BNP Paribas Funds Health Care Innovators | +15.53% | 0.11% |
| DAOL-GIHEALTH | 4.79% | Janus Henderson Horizon Biotechnology Fund | +2.88% | 2.32% |
| MHEALTHG | 3.81% | BGF World Healthscience Fund | +17.59% | 2.00% |
| MHEALTHRMF | 3.72% | BGF World Healthscience Fund | +18.34% | 1.81% |
| LHHEALTH-A | 3.61% | AB International Health Care Portfolio | +18.58% | 2.16% |
| TUSHEALTH-A | 2.98% | XLV | +23.08% | 1.31% |
| ASP-IHEALTH | 2.84% | several master funds (JHHBIU2 LX, ARKG US) | +20.72% | 2.83% |
| TGHSTARP | 2.31% | several master funds (BlackRock Global Funds - World Healthscience) | +15.44% | 1.90% |
| BCAP-XHEALTH | 1.32% | several master funds | +17.62% | 1.23% |
| PWIN | 1.32% | several master funds | +15.27% | 1.72% |
| Master fund | Thai funds using this route | Master fund's GILD weight |
|---|---|---|
| BGF World Healthscience Fund | 2 | 3.81% |
| several master funds | 2 | 1.32% |
| BNP Paribas Funds Health Care Innovators | 1 | 5.08% |
| Janus Henderson Horizon Biotechnology Fund | 1 | 4.79% |
| AB International Health Care Portfolio | 1 | 3.61% |
| State Street Health Care Select Sector SPDR ETF | 1 | 2.98% |
| several master funds (JHHBIU2 LX, ARKG US) | 1 | 2.84% |
| several master funds (BlackRock Global Funds - World Healthscience) | 1 | 2.31% |
